In 80 patients with relapsed/refractory large B-cell lymphoma, subcutaneous mosunetuzumab plus polatuzumab vedotin gave a best objective response rate of 77.5% vs 50.0% with rituximab plus polatuzumab (phase II). Median PFS 25.4 vs 6.4 months (HR 0.47); CRS 12.5%, all grade 1/2.
RCTn = 80
Chavez et al. A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma